"Boli" (also known as "Primobolan") is the drug that Alex Rodriguez admitted injecting into his body while playing with the Texas Rangers. During his recent press conference, he alleged that his cousin, Yuri Sucart (right), purchased the drug over-the-counter in the Dominican Republic and brought it to America.
However, news surfaced Friday that contradicts any real possibility that A-Rod's story is 100 percent true, as pharmacists from the D.R. told ESPN Deportes that "boli" has been illegal in their country since before 2001.
"What Alex Rodriguez stated at the press conference [in Tampa] doesn't make sense," [Dr. Pia] Veras said. "It is important for us to clarify that such substance has not been registered and is not currently registered for legal sale in Dominican pharmacies -- not now and the same applies for the years 2001 to 2003."
According to ESPN, a "representative of Rodriguez's" informed them that Dr. Veras, who apparently works for the Dominican's national drug regulatory agency, was incorrect. Dr. Veras allowed Deportes access to his agency's records, at which time they confirmed his statement. Additionally, Deportes spoke with a number of pharmacies around the country who maintained the same line as Veras: Primobolan has not been sold in the Dominican Republic, legally, since at least before 2001.
All of this speaks to a serious issue of truth with A-Rod's public confession at his recent press conference. It's possible that, with his statement that Sucart brought the drug to America, he has given himself a plausible deniability-styled alibi, but considering that this news broke on the same day as an alleged connection between A-Rod and banned trainer Angel Presinal, there's a very, very strong chance that the public's opinion of A-Rod's "truthful" admissions will be less than favorable now.
'Boli' Not Sold in Dominican Republic, According to D.R. Pharmacists originally appeared on MLB FanHouse on Fri, 20 Feb 2009 13:06:00 EST . Please see our terms for use of feeds.
Permalink | Email this | Linking Blogs | Comments
